We have shown previously that short-term treatment with spironolactone (S), testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:

Table 1

We conclude that long-term treatment with spironolactone, testolactone, and(after central puberty) deslorelin normalizes growth rate and bone maturation in boys with FMPP. The ultimate effect of this approach on adult height will require further study in a larger number of subjects.